Drug news
EU/UK hold on Vibativ is released and Clinagen will market in EU
Clinigen Group plc announced that the European Commission (EC) has ratified the positive opinion in January 2014 from the European Medicines Agency (EMA)�s Committee for Medicinal Products for Human Use (CHMP) to lift the Europe-wide suspension of Marketing Authorization for Vibativ.
Clinagen has licensed telavancin into its specialty pharmaceuticals business, Clinigen SP, from Theravance, Inc. for commercialization in Europe.